Could a tailored drug dose cut transfusions for kids with sickle cell?
NCT ID NCT05662098
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving children with sickle cell anemia a personalized dose of hydroxyurea can lower their need for blood transfusions. About 100 children in Uganda will receive a dose based on their own drug levels. Researchers will compare transfusion rates before and during treatment to see if the approach works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hydroxyurea
- What this could lead to
- If successful, this could show that personalized hydroxyurea dosing reduces the need for blood transfusions in children with sickle cell anemia.
- What could go wrong
- This is a very early, small study (100 children) without a comparison group, so results may not be conclusive or apply broadly. Hydroxyurea can lower blood counts and cause other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinja Regional Referral Hospital (JRRH), Department of Paediatrics, Sickle Cell Clinic
Jinja, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease